Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
Acquiring Company
Newcourt Acquisition
Acquired Company
Psyence Biomedical Ltd
TorontoTorontoPharmaceuticalBiotechnology ResearchDescription
Psyence Biomedical Ltd. has completed a merger with Newcourt Acquisition Corp, a special purpose acquisition company. Following this Business Combination, Psyence Biomedical Ltd. will be listed on Nasdaq with the new ticker symbols 'PBM' for common stock and 'PBMWW' for warrants. This strategic move will provide Psyence Biomedical Ltd. with additional funding, enabling it to accelerate its clinical trials and expand its market presence, ultimately contributing to advancements in the global health and wellness landscape.
Quick answer
Newcourt Acquisition is acquiring Psyence Biomedical Ltd, announced January 25, 2024. Newcourt Acquisition is based in Toronto, Ontario, Canada.
- How much did Newcourt Acquisition pay for Psyence Biomedical Ltd?
- The deal value was not disclosed.
- What does Newcourt Acquisition do?
- Newcourt Acquisition Corp is a special purpose acquisition company that focuses on facilitating mergers, share exchanges, asset acquisitions, share purchases, reorganizations, and similar business combinations with one..
- Where are Newcourt Acquisition and Psyence Biomedical Ltd based?
- Newcourt Acquisition is based in Toronto, Ontario, Canada. Psyence Biomedical Ltd is based in Toronto, Ontario, Canada.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biotechnology Research
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Blue Water Biotech Acquires Proteomedix As Part Of Transformation To Commercial Stage Oncology Company; Announces Name Change To Onconetix™ (December 18, 2023)
- Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc. (February 26, 2024)
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform (February 26, 2024)
- Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp (February 22, 2024)
- Petauri™ Acquires FORCE Communications (February 14, 2024)
- Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems (February 6, 2024)
Who to call at Newcourt Acquisition, and when
When Newcourt Acquisition changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Newcourt Acquisition raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Newcourt Acquisition, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Newcourt Acquisition. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Newcourt Acquisition makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Psyence Biomedical Ltd?
Psyence Biomedical Ltd was acquired by Newcourt Acquisition, based in Toronto. The deal was reported on January 25, 2024. Newcourt Acquisition is privately held.
When did Newcourt Acquisition acquire Psyence Biomedical Ltd?
Newcourt Acquisition's acquisition of Psyence Biomedical Ltd was reported on January 25, 2024. Psyence Biomedical Ltd. has completed a merger with Newcourt Acquisition Corp, a special purpose acquisition company. Following this Business Combination, Psyence Biomedical Ltd. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Psyence Biomedical Ltd do?
Psyence Biomed Ltd., is a pharmaceutical life science biotechnology company traded on the NASDAQ (NASDAQ:PBM), with a focus on botanical psychedelics. Psyence Biomed is the first Nasdaq-listed nature-derived psilocybin biopharma in the world. It is publicly traded (PBM), operating in Pharmaceutical, and is based in Toronto.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.